Abstract:Background The rapid and accurate detection of thyroid-stimulating hormone (TSH) receptor antibodies has always been an urgent need for the clinical diagnosis and management of Graves’ disease (GD). We aimed to evaluate the use of an automated thyroid-stimulating immunoglobulin (TSI) bridge immunoassay in the diagnosis of GD and to analyze the relationship between TSI and the degree of hyperthyroidism. Methods A total of 227 new-onset GD patients, 29 Hashimoto thyroiditis, 43 non-autoimmune thyroid diseases and 37 euthyroid controls were consecutively recruited. All participants accepted the measurement of their serum thyroid function and thyroid-associated antibodies, including TSI being measured by an Immulite 2000 bridge immunoassay and TSH receptor autoantibodies (TRAb) being measured by a third-generation Roche electrochemiluminescence immunoassay. The quantitative consistency between the TSI and TRAb detection methods was analyzed by using Passing-Bablok regression and Bland–Altman plots. The diagnostic performance for GD was assessed by receiver operating characteristic (ROC) curve analysis. Results Among 227 GD patients (174 females and 53 males, with a mean age of 39 years), the quantitative TSI was positively correlated with TRAb ( r = 0.8099). According to the cut-off values proposed by the manufacturers (TSI: 0.55 IU/L, TRAb: 1.75 IU/L), the positive rates of TSI and TRAb in new-onset GD patients were 96.92% and 95.15%, respectively. Both TSI and TRAb levels positively correlated with FT 4 levels (TSI: r = 0.243, TRAb: r = 0.317; all P < 0.001) and FT 3 levels (TSI: r = 0.288, TRAb: r = 0.360; all P < 0.001) in new-onset GD patients. The ROC analysis showed that the optimal TSI cut-off value was 0.577 IU/L for GD diagnosis in this Chinese population, with a sensitivity of 96.92% and a specificity of 97.25%, respectively. The optimal TRAb cut-off value of was 1.38 IU/L, with a sensitivity of 96.92% and a specificity of 99.08%. There were no significant differences between the cut-off values obtained through the ROC analysis and those provided by the manufacturer for both TSI and TRAb when calculating their sensitivity and specificity in diagnosing GD. Among the 8 newly diagnosed GD cases with discordant qualitative antibody results, TSI was more likely than TRAb to match the clinical diagnosis of GD (6 TSI-positive vs. 2 TRAb-positive patients). Conclusion The automated TSI bridge immunoassay was positively correlated with thyroxine levels in new-onset GD patients and was more likely to be consistent with the clinical diagnosis of GD than with that of TRAb. The positive Immulite 2000 TSI cut-off value of 0.577 IU/L for GD diagnosis in the Chinese population were close to the value recommended by the manufacturer.

Predictive value of bone turnover markers and thyroid indicators for bone metabolism in GD patients after treatment

The Changes of the Shear Wave Velocities on Thyroid Tissues in Patients with Graves Disease and Its Correlation with Thyrotropin

Associations Between Gut Microbiota and Thyroidal Function Status in Chinese Patients with Graves’ Disease

Prognostic value of post-ablation stimulated thyroglobulin in differentiated thyroid cancer patients with biochemical incomplete response: a bi-center observational study

Increased YKL-40 Levels Are Linked with Disease Severity of Initially Diagnosed Graves’ Disease

A clinical study on changes of bone biochemical parameters and bone mineral density in hyperthyroidism patients before and after treatment

Prediction of the Recurrence Risk of Graves' Disease after Antithyroid Drug Therapy

MiR-346 and TRAb as Predicative Factors for Relapse in Graves' Disease Within One Year

Thyroid-Stimulatory Antibody as a Predictive Factor for Graves’ Disease Relapse

Evaluation of the application of TSH receptor stimulating autoantibodies and the optimization of detection strategy in Graves’ disease

Study on the detection value of thyroid function and related antibody in Graves disease

Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer

Serum Ratio of Free Triiodothyronine to Thyroid-Stimulating Hormone: A Novel Index for Distinguishing Graves’ Disease From Autoimmune Thyroiditis

Clinical Evaluation of an Automated TSI Bridge Immunoassay in the Diagnosis of Graves’ Disease and Its Relationship to the Degree of Hyperthyroidism

Relationship between bone turnover markers and renal disease in elderly patients with type 2 diabetes: a cross-sectional study

Effect of drug treatment on bone mineral density and bone metabolism in patients with newly diagnosed hyperthyroidism

Comparison of Bone Mineral Density and Trabecular Bone Score in Patients with and without Vertebral Fractures and Differentiated Thyroid Cancer with Long-Term Serum Thyrotrophin-Suppressed Therapy

Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves’ disease and predictors of responsiveness to methimazole

Comparative analysis of bone turnover markers in bone marrow and peripheral blood: implications for osteoporosis

Assessment of the Correlation Between Vitamin D and T3, T4, FT3, FT4 and TSH Among Patients with Graves' Disease

Clinical value of bone turnover markers in the management of osteoporosis